Sponsor:
RxFunction Inc.
Code:
NCT06959277
Conditions
Peripheral Neuropathies
Peripheral Neuropathy Due to Chemotherapy
Peripheral Neuropathy With Type 2 Diabetes
Balance Control in Elderly
Gait Disorders
Eligibility Criteria
Sex: All
Age: 55+
Healthy Volunteers: Not accepted
Interventions
Walkasins
Fall Prevention Training
Brief summary:
Conditions
Peripheral Neuropathies
Peripheral Neuropathy Due to Chemotherapy
Peripheral Neuropathy With Type 2 Diabetes
Balance Control in Elderly
Gait Disorders
Study ID
NCT06959277
Start date
Jun 17, 2025
Status verified date
Oct, 2025
Completion date
Dec 31, 2027
Anticipated
Primary completion date
Jun, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 55+
Healthy Volunteers: Not accepted
Enrollment
200 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Walkasins User Group
other: Control Group
Interventions
Walkasins
Fall Prevention Training
Primary outcome measure
Central contacts
Locations
Dent Neurologic Institute
Recruiting
Amherst, New York, United States, 14226
Contacts
Principal Investigator:
Lixin Zhang, MD, PhD
University of Pittsburgh
Recruiting
Pittsburgh, Pennsylvania, United States, 15206
Contacts
University of Texas Medical Branch
Recruiting
Galveston, Texas, United States, 77555
Contacts
Principal Investigator:
Gregory Brusola, PhD, DPT, PT
Sponsor
RxFunction Inc.
Last update posted
Jul 14, 2026
Last verified
Oct, 2025
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by RxFunction Inc. on 2026-07-14.